Treatment results and prognostic factors in primary thyroid lymphoma patients: A Rare Cancer Network study

C. Onal, Y. X. Li, R. C. Miller, P. Poortmans, N. Constantinou, D. C. Weber, B. M. Atasoy, S. Igdem, M. Ozsahin, E. Ozyar

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5-and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.

Original languageEnglish (US)
Pages (from-to)156-164
Number of pages9
JournalAnnals of Oncology
Issue number1
StatePublished - Jan 2011


  • Chemotherapy
  • Combined modality treatment
  • Non-Hodgkin's lymphoma
  • Prognostic factors
  • Radiotherapy
  • Thyroid lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Treatment results and prognostic factors in primary thyroid lymphoma patients: A Rare Cancer Network study'. Together they form a unique fingerprint.

Cite this